MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Tempus AI and Flatiron Health Partner to Integrate Genomic Testing into OncoEMR for Enhanced Oncology Care

Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

FDA Approves Autolus’s CAR-T Therapy Aucatzyl for Relapsed or Refractory B-ALL in Adults

Biosimilars: Expanding Access to Precision Medicine through Affordable Biologic Therapies

IDEAYA Biosciences Secures Exclusive Worldwide License for Biocytogen’s BsADC Program IDE034 for Solid Tumor Treatment

Seer and Thermo Fisher Scientific Announce Strategic Collaboration to Advance Proteomics with Integrated Platform Solution

SystImmune Secures FDA Clearance for IND Application of Novel ADC Therapy BL-M17D1 for Advanced Solid Tumors

Medicare Expands Coverage for Adaptive Biotechnologies' clonoSEQ® MRD Test to Include Mantle Cell Lymphoma

Home
/
update
/
details

Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

NextEdge Admin

12 Nov 2024

2 min 28 sec

Flare Therapeutics Inc., a biotechnology company focused on developing precision medicines by targeting transcription factors, has entered a discovery partnership with Roche to advance new treatments for oncology. This collaboration combines Flare’s expertise in proteomics, mass spectrometry, and its proprietary electrophilic compound library with Roche's global capabilities in oncology to discover small-molecule drugs targeting previously undruggable transcription factors linked to cancer.

"Roche is a perfect partner for us, sharing our commitment to novel approaches for difficult-to-drug targets," said Rob Sims, Ph.D., Chief Scientific Officer and Co-founder of Flare Therapeutics. "Our platform has quickly built a clinical-stage pipeline, and this collaboration will broaden our capabilities, advancing treatment options for high unmet medical needs in oncology."

Flare will receive an initial payment of $70 million and may earn over $1.8 billion in development, commercialization, and milestone payments, plus royalties. The company will lead the discovery and preclinical work on multiple transcription factor targets in oncology, while Roche will oversee further clinical development and commercialization of successful candidates. Flare retains the right to co-fund development of one target to gain increased U.S. royalties for that asset.

Flare will maintain ownership of its existing pipeline, including FX-909, a lead program in advanced urothelial cancer, along with its prostate cancer program and other early-stage oncology initiatives. "This partnership with Flare allows us to leverage their expertise in transcription factor drug discovery," said Boris L. Zaïtra, Head of Roche Corporate Business Development, "and we look forward to creating novel therapeutic options in oncology."